Although Vaccaro and Colleagues initially demonstrated that targeted therapy could prime macrophage activity in NSCLC [38], limited information exists regarding the effects of TKIs in different ALK+ malignancies. This evidence concerns the gene ALK and non-small cell lung carcinoma.